- Home
- DOYU vs MOLN Comparison
DOYU vs MOLN Comparison
Compare DOYU & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DOYU | MOLN |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.0M | 144.0M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DOYU | MOLN |
|---|---|---|
| Price | $4.98 | $4.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $8.38 |
| AVG Volume (30 Days) | ★ 15.7K | 2.1K |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.28 | $3.36 |
| 52 Week High | $9.34 | $5.36 |
Technical Indicators
Market Signals| Indicator | DOYU | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 55.70 |
| Support Level | $4.71 | $4.04 |
| Resistance Level | $5.07 | $4.54 |
| Average True Range (ATR) | 0.16 | 0.12 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 56.25 | 89.54 |
Price Performance
Historical ComparisonAbout DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.